Recce Pharmaceuticals Ltd (RCE) is a drug discovery and development business commercialising a new class of synthetic antibiotics with broad spectrum activity designed to address the global health challenge of antibiotic resistant superbugs. Its patented lead candidate known as RECCE 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms.
Recce Pharmaceuticals Ltd belongs to Health Care sector and under industry of Pharmaceuticals. You can get more information about this company via their website: http://www.recce.com.au.
This a small cap company with market cap of 175 millions.
Compared to Market and Sector
The following table compares the company to Market and Sector based on Earning, Price/Earning ratio(P/E), Price/Book ratio (P/B) and PE growth.
Company PE is less than both sector and market. while Company PB is greater than both sector and market. On the other hand, Company Earning is less than both sector and market.
Dividend Growth Chart
The following chart shows you how rce dividend grows in the recent years.